ICU patients may need custom doses of common antifungal
NCT ID NCT02164890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the antifungal drug micafungin is processed in the bodies of 60 critically ill ICU patients with invasive candidiasis. Researchers took multiple blood samples to measure drug levels and understand why some patients might not get enough medicine. The goal is to improve dosing for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- micafungin
- What this could lead to
- If successful, this could help doctors tailor micafungin doses for ICU patients, potentially improving treatment success.
- What could go wrong
- This is a small, completed pharmacokinetic study, not a treatment trial. It may not lead to new dosing guidelines or directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Montpellier
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a quick PCR test speed up lifesaving fungal infection diagnosis?
- Blood biomarkers may let ICU patients stop antifungals earlier
- Could 7 days of antifungals be enough for kids with blood infections?
- Candida resistance study pulled before it began
- New blood tests could speed up detection of deadly fungal infections
- New drug could shield transplant patients from deadly fungal infections